TPMT and NUDT15

Use this genotyping test to assess genetic risk for severe myelosuppression with standard dosing of thiopurine drugs in individuals for whom thiopurine therapy is being considered or who have had an adverse reaction to thiopurine therapy. This test may be performed irrespective of whether thiopurine therapy is currently being administered. 

For enzyme phenotyping prior to thiopurine treatment, refer to Thiopurine Methyltransferase, RBC (0092066). For thiopurine dosing optimization, refer to Thiopurine Metabolites in Red Blood Cells (3016503).